Localized treatment of solid tumors with radiation triggered liposomes

Rejuvenics Technologies正在开发一项专利技术，该技术利用局部电离辐射触发封装在放射敏感脂质体中的化疗药物的释放。这种首创的方法同时针对实体肿瘤进行放射治疗和化疗；尽量减少对重要器官的毒性暴露，并可能提高疗效。在这项I期计划中，Rejuvenics将与阿肯色大学医学科学专家合作，通过三个目标开发化疗放射触发脂质体（RTLs）： 1)选择先导化疗药物包封在RTL001中，并表征RTL001的辐射剂量反应；2)测定RTL001在小鼠体内的生物分布和药代动力学；3)评价RTL001在小鼠体内的局部抗肿瘤作用。这些结果代表了重要的临床前里程碑，对FDA预提交过程至关重要，因为Rejuvenics准备进行II期研究。我们努力证明rtl能够实现更安全、可控的化疗递送，以治疗非转移性肺癌，克服全身毒性，并改善数百万癌症患者的临床结果。Rejuvenics的癌症、药物开发和放射研究人员以及行业专家团队准备成功地执行这项研究，向美国国立卫生研究院提供切实的结果，并沿着商业化的道路推进产品开发的临床测试。

Rejuvenics Technologies is developing a patented technology that utilizes localized ionizing radiation to trigger release of chemotherapeutic agents encapsulated inside radio-sensitive liposomes. This first-of-its- kind methodology simultaneously targets radiotherapy and delivery of chemotherapeutics to solid tumors; minimizing toxic exposure to vital organs and potentially enhancing efficacy. In this Phase I proposal, Rejuvenics will develop encapsulated chemotherapy Radiation-Triggered Liposomes (RTLs), through three Objectives in collaboration with experts at the University of Arkansas for Medical Sciences: 1) Select the lead chemotherapeutic to encapsulate in RTL001 and characterize the radiation dose response of RTL001; 2) Determine biodistribution and pharmacokinetics of RTL001 in mice; and 3) Assess localized anti-tumor efficacy of RTL001 in mice. These results represent key pre-clinical milestones important to the FDA Pre-Submission process as Rejuvenics prepares for Phase II studies. We endeavor to demonstrate the ability of RTLs to achieve safer, controlled delivery of chemotherapy to treat non-metastatic lung cancer, overcome systemic toxicity, and improve clinical outcomes for millions of cancer patients. Rejuvenics' team of cancer, drug development and radiation researchers and industry experts is prepared to successfully execute this study, deliver tangible results to the NIH, and advance the product development toward clinical testing along the path to commercialization.